BMY SEC Filings

Bristol Myers Squibb (BMY) has filed its 2025 10-K, reporting on a year characterized by strategic advancements in its product pipeline and ongoing operational management. The company's performance is underpinned by its diverse portfolio, with a strong emphasis on research and development to fuel future growth and maintain a competitive edge in the biopharmaceutical market. Investors will want to note the company's ongoing efforts in acquisitions, divestitures, and licensing, which are crucial for portfolio optimization and addressing patent expirations. Key areas of focus for the investor include the company's robust pipeline, intellectual property protection, and market access strategies. Management's Discussion and Analysis (MD&A) section will provide critical insights into the financial condition, results of operations, and risk factors, offering a comprehensive view of the company's financial health and future outlook. Understanding the competitive landscape, pricing pressures, and regulatory environment is also paramount for assessing BMY's long-term prospects and resilience.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 5, 2026, to announce its financial results for the fourth quarter and full year of 2025. The filing includes a press release (Exhibit 99.1) detailing these results and a presentation (Exhibit 99.2) covering financial and operating initiatives. Investors should refer to these documents, available on the company's website, for a comprehensive understanding of BMY's recent performance and strategic direction. Both the press release and presentation reference non-GAAP financial information. The company emphasizes that reconciliations between non-GAAP and GAAP measures, along with explanations for the use of non-GAAP figures, are provided within the press release. Investors are advised to review these reconciliations carefully when evaluating the company's financial health and operational efficiency.

Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on January 12, 2026, to disclose an investor presentation made available on their website on January 11, 2026. This presentation, attached as Exhibit 99.1, is intended to provide updates and insights to investors regarding the company's strategic direction, performance, and future outlook. While the filing itself does not contain new financial results or material events beyond the presentation, it serves as a crucial communication channel for investors seeking the latest information directly from the company. Investors are encouraged to review the presentation for details on BMY's ongoing initiatives, pipeline updates, and market positioning, as this is the primary vehicle through which the company is sharing this information in connection with this filing.

Bristol Myers Squibb Company (BMY) has filed an 8-K report detailing the results of its previously announced cash tender offers for its outstanding notes. The company announced early participation results on November 17, 2025, and on November 18, 2025, it released the accepted amounts and pricing terms of these offers. These tender offers are part of a strategy to manage its debt obligations, with full details provided in the Offer to Purchase document dated November 3, 2025. Investors should note that this filing primarily concerns debt management and does not represent an offer to buy or sell equity securities. The early participation results and final pricing indicate the company's progress in its debt restructuring efforts, which could impact its financial leverage and interest expense going forward. The full financial implications will be clearer as the settlement process concludes and is reflected in future financial statements.

Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973% to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses. Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.

Bristol-Myers Squibb Company (BMY) has announced the initiation of cash tender offers to repurchase up to $7 billion of its outstanding notes. This move suggests the company is actively managing its debt obligations, potentially aiming to optimize its capital structure or take advantage of favorable market conditions for debt buybacks. Investors should note that this tender offer is a significant financial maneuver that could impact the company's liquidity and leverage ratios. The details of the offer, including pricing and specific notes targeted, are outlined in the company's Offer to Purchase dated November 3, 2025. The aggregate purchase price is capped at $7 billion, with further limitations specified for different note pools.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 30, 2025, to announce its financial results for the third quarter of 2025. The filing primarily includes a press release detailing these results and a presentation covering financial and operating initiatives discussed during the company's conference call. Investors should review these furnished documents for a comprehensive understanding of BMY's performance and strategic direction. The company has made available both the Earnings Press Release and the Bristol Myers Presentation on its website. These materials contain forward-looking information, including references to non-GAAP financial measures. BMY has also provided reconciliations for these non-GAAP figures to their comparable GAAP counterparts, which are crucial for investors seeking to interpret the financial performance accurately. It is important to note that this information is furnished and not considered "filed" under the Securities Exchange Act, meaning it does not carry the same liability implications as formally filed documents, but it is still material for investment decisions.

Bristol Myers Squibb (BMY) reported its financial results for the period ending September 29, 2025. The company's third-quarter performance indicates a stable financial position, with key metrics expected to be closely scrutinized by investors in light of ongoing market dynamics and product pipeline developments. Management's Discussion and Analysis will provide crucial insights into revenue drivers, operating expenses, and the company's strategic outlook, particularly concerning R&D investments and potential commercial successes. Investors should pay close attention to the company's revenue generation across its key therapeutic areas, the impact of any patent expirations or new drug approvals, and the company's cash flow from operations. The balance sheet details will reveal the company's debt levels and liquidity position, while the cash flow statement will illustrate how the company is investing in its future growth and returning capital to shareholders. Understanding these elements is vital for assessing BMY's ongoing value and future prospects.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 31, 2025, to disclose its financial results for the second quarter of 2025. The filing primarily serves to furnish the earnings press release and a related presentation, both of which are available on the company's website. These documents contain detailed financial performance information, including both GAAP and non-GAAP measures, which investors should review for a comprehensive understanding of the company's operational and financial condition during the quarter. The earnings press release and presentation provide crucial insights into BMY's performance, strategic initiatives, and outlook. Investors are encouraged to access these furnished exhibits for specifics on revenue, profitability, and any forward-looking statements or strategic developments discussed. The company has also highlighted that reconciliations between GAAP and non-GAAP figures are available within these provided materials.

Bristol Myers Squibb (BMY) has filed its second quarter 2025 10-Q, providing investors with an update on its financial performance and operational developments. The report covers the period ending June 29, 2025, and highlights the company's ongoing focus on strategic growth initiatives and product portfolio management. Investors should pay close attention to the company's revenue trends, research and development investments, and any updates on key litigation or regulatory matters that could impact future performance.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the departure of Dr. Samit Hirawat, Chief Medical Officer and Head of Development. Dr. Hirawat will transition to an advisory role effective August 1, 2025, and will depart the company by November 1, 2025. This change in key leadership, particularly in the development function, may warrant investor attention as it could impact the company's research and development pipeline and strategic direction. In connection with his departure, Dr. Hirawat is entitled to standard severance benefits, pro-rated vesting of certain equity awards (Market Share Units and Performance Share Units), and a prorated annual incentive payout for 2025. The details of his compensation package are outlined in accordance with the company's established plans and agreements. Investors should monitor any future disclosures for updates on leadership transitions and their potential implications for BMY's operational and financial performance.

Bristol Myers Squibb Co. (BMY) held its Annual Meeting of Shareholders on May 6, 2025, as detailed in this 8-K filing. The meeting's primary outcomes revolved around shareholder votes on key corporate governance and executive matters. Notably, all 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and oversight. The company also received shareholder approval for the compensation of its named executive officers through an advisory vote, suggesting alignment between executive pay and shareholder interests. Furthermore, shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2025. In contrast, two shareholder proposals, one concerning Corporate Financial Sustainability and another requesting the cessation of DEI (Diversity, Equity, and Inclusion) Efforts, did not receive sufficient support to pass. These results reflect shareholder sentiment on strategic priorities and corporate social responsibility initiatives.

Bristol Myers Squibb (BMY) has filed its quarterly report for the period ending March 30, 2025. The filing provides investors with an overview of the company's financial performance, operational highlights, and risk factors. While the provided excerpt does not contain specific financial figures for the quarter, it outlines the key sections investors should review, including the Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, as well as Management's Discussion and Analysis (MD&A) for detailed insights into the company's financial condition and results of operations. Investors should pay close attention to the MD&A section for management's commentary on revenue drivers, cost management, and strategic initiatives. The report also details market risk exposures and information regarding legal proceedings, risk factors, and unregistered sales of equity securities. Investors are encouraged to review these sections to gain a comprehensive understanding of potential risks and ongoing corporate activities that could impact the company's future performance. The inclusion of product brand names and trademark information in the notes to the financial statements suggests a focus on the company's pharmaceutical portfolio and intellectual property.

Bristol Myers Squibb Company (BMY) has filed an 8-K report on April 24, 2025, primarily to announce its first-quarter 2025 financial results and provide related presentations. The filing includes an Earnings Press Release (Exhibit 99.1) and a Bristol Myers Presentation (Exhibit 99.2), both dated April 24, 2025, detailing the company's performance and strategic initiatives for the period. Investors should note that both documents contain references to non-GAAP financial information, with reconciliations provided in the Earnings Press Release. This report serves as the formal vehicle for disseminating BMY's Q1 2025 financial outcomes and outlook. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished exhibits for a comprehensive review of operational and financial conditions. The company also highlights that the information provided under Regulation FD is furnished and not deemed 'filed' for certain regulatory purposes, and they reserve the right to remove the presentation from their website.

Bristol Myers Squibb Company (BMY) has filed an 8-K report announcing the upcoming retirement of Sandra Leung, Executive Vice President and General Counsel. Ms. Leung intends to retire in 2025 and will remain with the company for a transition period to ensure a smooth handover of her responsibilities. This change in a key executive role warrants investor attention as leadership transitions can sometimes impact strategic direction and operational continuity. Ms. Leung is eligible for retirement benefits under the company's existing compensation plans. While the report does not detail the specific benefits, it confirms adherence to established policies. Investors should monitor future filings for announcements regarding Ms. Leung's successor, as the appointment of a new General Counsel is a significant development for the company's legal and governance framework.

Bristol Myers Squibb (BMY) has filed its 2024 10-K, providing a comprehensive overview of its business, financial performance, and strategic direction. The report highlights the company's ongoing efforts in research and development, product portfolio management, and its approach to navigating the complex regulatory and competitive landscape within the pharmaceutical industry. Investors should pay close attention to the company's pipeline, potential market access challenges, and its strategies for maintaining long-term growth and shareholder value amidst evolving healthcare dynamics. The filing details the company's financial condition and results of operations, offering insights into revenue drivers, cost structures, and cash flow generation. Management's Discussion and Analysis is expected to provide crucial context on the factors influencing BMY's performance, including the impact of key product sales, patent expirations, and strategic investments. Furthermore, the report addresses risk factors, legal proceedings, and corporate governance, providing a holistic view for stakeholders assessing the company's overall health and future prospects.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 6, 2025, to announce its financial results for the fourth quarter and full year of 2024. The filing includes a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance. This report also references a supplemental presentation available on the company's website, offering further insights into financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial measures, with reconciliations provided in the press release. This 8-K serves as a notification and furnishing of material information, rather than a definitive filing with liabilities under Section 18 of the Exchange Act, for the information furnished under Item 7.01. The company's decision to make the presentation available on its website is subject to change. Investors seeking detailed financial performance, strategic updates, and forward-looking statements will find the most crucial information within the furnished press release and presentation materials.

Bristol-Myers Squibb Company (BMY) filed a Current Report on Form 8-K on January 13, 2025, to disclose the posting of an investor presentation on its website. This presentation, dated January 13, 2025, is attached as Exhibit 99.1 to the filing and is available on the company's investor relations website. The filing itself does not contain substantive new financial information but serves to make the investor presentation publicly accessible in accordance with Regulation FD. Investors should note that this filing is primarily a notification of available information rather than a report of material events or financial results. The attached investor presentation is expected to contain the most recent updates, strategic insights, and potentially forward-looking statements from the company. While the information furnished is not deemed "filed" for regulatory purposes, it is important for investors seeking the latest company communications.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 31, 2024, to announce its third-quarter 2024 financial results. The report primarily serves to furnish a press release detailing these results and a supplementary presentation that was made available during the company's earnings conference call. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational performance of the company during the third quarter. The company also notes that both the press release and the presentation contain non-GAAP financial information. Reconciliations of these non-GAAP measures to their nearest GAAP equivalents, along with explanations for their use, are provided within the furnished press release. Investors are advised to review these materials in conjunction with the press release to gain a comprehensive understanding of BMY's reported performance and strategic updates.

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending September 29, 2024, presenting a snapshot of its financial performance and operational standing. While the provided excerpt doesn't contain detailed financial figures, it outlines the key sections investors should scrutinize, including the Consolidated Statements of Earnings and Comprehensive Income, Balance Sheets, and Cash Flows. Management's Discussion and Analysis (MD&A) will be crucial for understanding the drivers behind the company's performance, strategic decisions, and outlook. Investors should pay close attention to revenue trends, profitability, cash generation, and any significant updates on product pipelines, regulatory approvals, or litigation, as detailed in the subsequent sections of the filing.

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending June 29, 2024, on July 25, 2024. While the filing provides detailed financial statements and management's discussion, it does not contain the actual financial performance figures (revenue, net income, etc.) in the provided snippet. Investors should refer to the full filing for specific performance metrics. The document outlines the structure of the report, indicating sections covering financial statements, management's discussion and analysis, market risk, legal proceedings, risk factors, and other information. Key areas to scrutinize in the full report will include the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" for insights into the company's performance drivers, challenges, and strategic outlook. Investors should pay close attention to Item 1A, "Risk Factors," as it will detail any new or evolving risks that could impact BMY's future financial performance. The report's structure suggests a comprehensive review of the company's operations and financial health. The absence of specific financial data in the provided excerpt means a deeper dive into the full 10-Q is essential for investors to understand the quarter's financial results, cash flow generation, and overall financial position.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 26, 2024, to announce its financial results for the second quarter of 2024. The report primarily references an Earnings Press Release and a related Investor Presentation, both dated July 26, 2024, which contain detailed financial and operational information. Investors should refer to these furnished documents for a comprehensive understanding of the company's performance during the quarter. The company has made these materials available on its website and through a conference call and webcast. It's important for investors to note that both the press release and presentation include non-GAAP financial information. The company has provided reconciliations between non-GAAP and GAAP measures within the Earnings Press Release, along with explanations for the use of these non-GAAP figures. Investors are advised to review these reconciliations and the company's official filings for complete financial transparency.

Bristol-Myers Squibb Company (BMY) announced a key addition to its Board of Directors, electing Michael R. McMullen as a new member effective July 1, 2024. This appointment increases the Board's size to eleven members. Mr. McMullen brings extensive executive leadership experience, notably as the former CEO of Agilent Technologies, where he significantly grew the company's market capitalization and drove operational and cultural transformations. His background in leading global operations and a proven track record of delivering shareholder returns are expected to be valuable assets to BMY. Furthermore, Mr. McMullen's expertise will be leveraged as he joins the Audit Committee of the Board. His compensation for board service aligns with the company's standard arrangements for non-employee directors, including an annual retainer and deferred share units. The company also noted the independence of Mr. McMullen under NYSE listing standards and its own board standards, with no disclosed arrangements or related party transactions influencing his appointment.

Bristol-Myers Squibb Company (BMY) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on May 7, 2024. The most significant event for investors is the shareholder approval of an amendment to the company's Certificate of Incorporation. This amendment, effective May 7, 2024, aims to eliminate or limit the monetary liability of specified executive officers for breaches of the duty of care. This change in governance structure could impact executive decision-making and the company's overall risk profile. In addition to the liability amendment, the report indicates that shareholders overwhelmingly re-elected all 10 director nominees, approved the compensation of named executive officers on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2024. Conversely, two shareholder proposals—one advocating for an independent Board Chairperson and another for adopting a Board policy on executive retention of significant stock—did not receive majority approval.

Bristol Myers Squibb (BMY) reported its first-quarter 2024 financial results, revealing a mixed performance with continued strategic evolution. The company saw a decline in revenue year-over-year, largely attributed to key product headwinds and a strategic pivot towards new growth drivers. Despite revenue challenges, BMY demonstrated effective cost management and a strong commitment to research and development, which are crucial for its long-term pipeline success. Investors should closely monitor the progress of its newly launched products and pipeline advancements, as these will be critical for offsetting patent expirations and driving future top-line growth. The company's cash flow generation remains robust, supporting its ongoing investment in R&D and potential strategic acquisitions.

Bristol-Myers Squibb Company (BMY) filed an 8-K on April 25, 2024, primarily to announce its first quarter 2024 financial results. The filing includes a press release detailing these results and a presentation discussing financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial information, with reconciliations provided in the press release. This report serves as a formal notification of the Q1 2024 performance and provides supplementary materials for a deeper understanding of the company's financial standing and strategic direction. The company has made these materials available on its website and through a webcast, allowing investors to access detailed financial data and management's commentary on the quarter's performance and outlook.

Bristol Myers Squibb Company (BMY) announced a change in its Board of Directors composition. Gerald Storch has informed the Board that he will not seek re-election at the upcoming 2024 Annual Meeting of Shareholders, scheduled for May 7, 2024. This decision means Mr. Storch will step down from his board position after this meeting. Following this departure, the Board has decided to reduce its size from its current number to ten directors, effective immediately after the 2024 Annual Meeting. Investors should monitor any further announcements regarding director nominations or changes in board committee memberships, as these can sometimes signal strategic shifts or governance considerations, though the primary impact here appears to be a routine board refreshment.

Bristol-Myers Squibb Company (BMY) has announced the successful completion of its acquisition of Karuna Therapeutics, Inc. (Karuna) as of March 17, 2024. This strategic move involves BMY acquiring all outstanding shares of Karuna common stock for a cash payment of $330.00 per share, excluding certain specified shares. The transaction represents a significant investment by BMY in Karuna's pipeline and potential. Investors should note that this acquisition marks a pivotal step for Bristol-Myers Squibb, signaling its commitment to expanding its therapeutic areas, likely focusing on Karuna's specialized drug development programs. The financial implications of this $330 per share cash transaction will be reflected in BMY's future financial statements, and further details on the integration and impact are anticipated.

Bristol Myers Squibb Company (BMY) announced the completion of a significant public offering of debt securities, raising a total of $11.75 billion. This offering includes a variety of notes with fixed and floating interest rates, maturing between 2026 and 2064. The primary purpose of these proceeds is to fund the cash consideration for the proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., along with associated fees and expenses. Any remaining net proceeds will be used for general corporate purposes. The offering was completed as planned, irrespective of the acquisition closings. However, the indenture includes provisions for a Special Mandatory Redemption for most of the notes if the Karuna acquisition is not consummated by specific deadlines or if BMY decides not to pursue it. This offers a degree of protection to noteholders in the event the acquisitions do not proceed, with a redemption price of 101% of the principal amount plus accrued interest.

Bristol Myers Squibb Company (BMY) announced a key leadership change within its finance department. Effective February 15, 2024, Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer brings extensive experience to this role, having been with the company since 2001 and most recently serving as Senior Vice President, Finance, Treasury and Tax Operations since 2021. This appointment signifies a transition as the current Senior Vice President and Controller, Ms. Sharon Greenlees, will be moving to another role within the company. Investors should view this as a normal course of business succession planning. Mr. Holzer's long tenure and diverse financial leadership positions within BMY suggest a stable internal promotion, which typically indicates continuity in financial strategy and operations. The filing also notes that Mr. Holzer is not involved in any reportable related-party transactions or arrangements related to his appointment.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report primarily to address an unsolicited "mini-tender" offer from Tutanota LLC. Tutanota is attempting to purchase a small percentage of BMY's outstanding shares (less than 0.025%) at a price of $55.00 per share. The company explicitly states it does not endorse this offer and advises its shareholders not to tender their shares. This action is a protective measure for shareholders, aiming to prevent them from accepting an offer that is likely significantly below the market value of BMY stock and potentially subject to unfavorable terms. Investors should be aware that this 8-K filing is a cautionary announcement, not an indication of significant company performance or strategic shifts. The unsolicited offer is from a third party and is not associated with Bristol-Myers Squibb. The company's recommendation against tendering shares suggests that shareholders who accept this offer may be selling their stock at a discount. Shareholders who have already tendered are advised to consider withdrawing their shares before the offer's expiration on February 23, 2024.

Bristol Myers Squibb (BMY) has filed its 2023 Annual Report, detailing a year characterized by strategic adjustments and a focus on its core therapeutic areas. The company has continued its efforts in research and development to bolster its pipeline and navigate patent cliffs. Investors should pay close attention to the company's progress in key therapeutic areas, particularly in oncology and immunology, where significant R&D investments are being made. The report also highlights ongoing efforts in portfolio management, including potential acquisitions, divestitures, and licensing agreements, aimed at optimizing its product mix and long-term growth trajectory. Financial performance for 2023 reflects the company's ongoing strategies, with the Management's Discussion and Analysis providing a deeper dive into revenue drivers, cost management, and cash flow generation. The company's commitment to innovation remains a central theme, underscoring the importance of its R&D pipeline in driving future revenue and maintaining competitive advantage in the dynamic pharmaceutical landscape. Investors are encouraged to review the risk factors section, which outlines potential challenges and uncertainties impacting the business.

Bristol Myers Squibb Company (BMY) filed an 8-K on February 2, 2024, to announce its financial results for the fourth quarter and full year of 2023. The filing primarily includes the press release detailing these results (Exhibit 99.1) and a supporting presentation (Exhibit 99.2), both of which were made available on February 2, 2024. These documents provide key financial and operational updates for investors to assess the company's performance. The company is utilizing this 8-K filing to furnish the earnings press release and presentation materials, which contain both GAAP and non-GAAP financial information. Investors are directed to the press release for reconciliations between these measures. The filing itself does not introduce new material events beyond the financial results announcement, but investors should review the furnished exhibits for a comprehensive understanding of BMY's 2023 performance and outlook.

Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 8, 2024, primarily to disclose an investor presentation that was posted on their website on the same date. This presentation is available as an exhibit to the filing. While this filing does not contain new financial results or significant business updates beyond the presentation, it serves as a channel for the company to communicate with its investors and the market. Investors should review the attached presentation for any information or insights Bristol-Myers Squibb is providing to the investment community regarding its business, strategy, or outlook.

Bristol-Myers Squibb Company (BMY) announced on December 22, 2023, that it has entered into a definitive agreement to acquire Karuna Therapeutics, Inc. (Karuna) for $330.00 per share in cash. This transaction represents a significant strategic move for BMY, aiming to bolster its neuroscience pipeline with Karuna's promising drug candidate, KarXT, for treating schizophrenia and other neurological disorders. The acquisition is structured as a merger, with Karuna surviving as a wholly-owned subsidiary of BMY. The deal is subject to customary closing conditions, including the approval of Karuna's stockholders. Investors should monitor regulatory approvals and the timeline for closing, as well as the integration of Karuna's assets into BMY's portfolio, which could significantly impact future growth and product offerings.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the successful completion of a substantial public offering of notes totaling $4.5 billion. The offering comprises four tranches with varying interest rates and maturity dates, ranging from 2031 to 2063. The company intends to utilize the net proceeds from this offering for general corporate purposes, with a specific mention of financing the proposed acquisition of Mirati Therapeutics, Inc., and associated fees and expenses. This issuance represents a strategic move to secure funding for significant future investments and operational needs. The notes are governed by an indenture, which includes customary covenants and restrictions related to incurring secured debt, engaging in sale/leaseback transactions, and significant corporate actions like mergers. The company retains the option to redeem the notes prior to maturity, with redemption terms outlined for both 'make-whole' provisions before a certain date and at par value on or after the applicable 'Par Call Date.' Investors should note the specific interest rates and maturity dates, as well as the company's flexibility in early redemption.

This 8-K/A filing from Bristol Myers Squibb (BMY) provides an update on leadership transitions and associated compensation, primarily concerning the CEO role. Effective November 1, 2023, Dr. Christopher Boerner will assume the CEO position, taking over from Dr. Giovanni Caforio, who will transition to Executive Chairman. This amendment clarifies that Dr. Caforio will not stand for re-election to the Board and will retire on April 1, 2024, at which point Dr. Boerner will also assume the role of Chairman of the Board. The filing details Dr. Boerner's new compensation package as CEO, including a base salary of $1,500,000, a target bonus of 150% of base salary, and additional long-term incentive awards valued at $1,600,000. Dr. Caforio's compensation remains unchanged during his transition to Executive Chairman, but he will not receive further long-term incentive awards. Investors should note the structured handover and the confirmation of Dr. Boerner's leadership into the Chairman role.

Bristol Myers Squibb (BMY) reported its third-quarter 2023 financial results, demonstrating resilience in its key therapeutic areas despite ongoing challenges. The company's performance was shaped by a mix of strong execution in certain product lines and the continued impact of patent expirations on older revenue streams. Investors should note the strategic focus on a diversified portfolio and pipeline development as key drivers for future growth, with management emphasizing progress in clinical trials and regulatory submissions. The company is navigating a complex market, balancing innovation with the need to manage the lifecycle of its established products.

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 26, 2023, to announce its third-quarter 2023 financial results. The filing primarily includes a press release detailing these results and a related presentation shared during their earnings conference call. Investors should note that the company is referencing non-GAAP financial information, and reconciliations to GAAP measures are available in the furnished press release. While the specific financial figures are not detailed within this 8-K, the furnishing of the press release and presentation indicates that BMY has disclosed its Q3 performance and strategic updates. Investors are encouraged to review Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Bristol Myers Presentation) for the complete financial details, key performance indicators, and forward-looking statements.

Bristol-Myers Squibb Company (BMY) announced on August 9, 2023, that it has entered into accelerated share repurchase (ASR) agreements to buy back an aggregate of $4.0 billion of its common stock. These transactions are part of a previously authorized multi-year share repurchase program and are being executed with major financial institutions including Bank of America, Citibank, JPMorgan Chase, and Morgan Stanley. The ASR transactions are designed to return capital to shareholders and reflect the company's confidence in its financial position and future prospects. While an initial portion of the shares will be delivered promptly, the final number of shares repurchased will be determined by volume-weighted average prices over the repurchase period, with potential adjustments. This move is a significant capital allocation decision that investors will want to monitor for its impact on earnings per share and overall shareholder value.

Bristol Myers Squibb (BMY) reported its financial results for the second quarter ending June 29, 2023. The company showcased solid revenue performance driven by its key in-line and new product portfolio, demonstrating continued growth momentum. While facing some headwinds, the overall financial health appears robust, supported by strategic advancements and a strong cash flow generation, positioning the company for future development and shareholder returns. Investors should note the company's focus on strategic pipeline progression and potential upcoming product launches, which are crucial for long-term value creation. The report details the company's operational performance, financial condition, and risk factors, offering a comprehensive view for stakeholders assessing BMY's market position and future prospects.

Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2023, to report its second quarter 2023 financial results and related presentations. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for comprehensive information on the company's performance. These documents, available on the company's website, are crucial for understanding BMY's operational and financial standing for the period. Investors should note that the press release and presentation include non-GAAP financial measures, with reconciliations provided in the press release. The company has furnished these documents under Items 2.02 and 7.01, meaning they are not considered officially "filed" for purposes of Section 18 of the Exchange Act but are important for understanding the company's disclosed results and forward-looking initiatives.

Bristol Myers Squibb Company (BMY) announced significant leadership changes and reported the outcomes of its Annual Meeting of Shareholders held on May 2, 2023. The most notable development is the appointment of Dr. Christopher Boerner as Chief Operating Officer effective April 26, 2023, and his subsequent appointment as Chief Executive Officer effective November 1, 2023. Dr. Boerner has also been elected to the Board of Directors, increasing its size to twelve members. While he is a key executive, the Board has determined he is not independent under NYSE standards and will not serve on any Board committees, nor will he receive compensation for his director role. The Annual Meeting also saw shareholders re-elect all eleven incumbent directors, approve the compensation of named executive officers on an advisory basis, and vote for an annual advisory vote on executive compensation. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2023. However, shareholder proposals regarding an independent Board Chairperson and improvements to special shareholder meetings did not pass.

Bristol Myers Squibb (BMY) reported its first quarter 2023 results, showing a notable increase in revenue driven by strong performance in its key therapeutic areas. The company continues to navigate patent expirations and integrate recent acquisitions, which are impacting its product mix and overall financial trajectory. Investors should pay close attention to the company's product pipeline, ongoing litigation, and its strategy for managing the loss of exclusivity on certain blockbuster drugs. While the current quarter demonstrates revenue growth, sustained long-term growth will depend on successful new product launches and effective cost management. The company's strategic focus remains on advancing its diversified portfolio, particularly in oncology, immunology, and cardiovascular disease. Management's discussion highlights investments in research and development aimed at building a robust pipeline for future growth. However, the impact of competition and market dynamics on revenue streams and profitability needs careful monitoring. The balance sheet appears stable, but cash flow generation and debt levels should be reviewed in the context of future capital allocation and strategic investments.

Bristol-Myers Squibb Company (BMY) filed an 8-K on April 27, 2023, to report its financial results for the first quarter of 2023. The filing includes a press release detailing the company's performance and a presentation on financial and operating initiatives. Investors should note that these releases contain both GAAP and non-GAAP financial information, with reconciliations provided in the press release. The primary purpose of this 8-K is to formally disseminate BMY's Q1 2023 financial outcomes and strategic updates. While the filing itself does not contain new operational data, it directs readers to the furnished exhibits for detailed financial figures and forward-looking discussions. Investors are encouraged to review these attached documents for a comprehensive understanding of the company's recent financial condition and performance.

Bristol Myers Squibb Company (BMY) announced a significant leadership transition, with current Chairman and CEO Giovanni Caforio, M.D., set to retire as CEO on November 1, 2023. Dr. Caforio will remain Chairman until his CEO retirement and then transition to Executive Chairman for a period to be determined. This marks the end of an era for a key figure in the company's recent history. Following this announcement, the Board of Directors appointed Christopher Boerner, Ph.D., as the new Chief Executive Officer, effective November 1, 2023. Dr. Boerner, currently serving as Chief Operating Officer, has been with BMY since 2015 and has held various senior leadership roles, including Executive Vice President and Chief Commercialization Officer. His appointment signals a move towards internal succession for the top leadership role.

Bristol-Myers Squibb Company (BMY) filed an 8-K report on February 27, 2023, to provide an update regarding Contingent Value Rights (CVRs) associated with the 2019 acquisition of Celgene Corporation. The report specifically addresses the Abraxane® product and its related CVRs. Investors should note that the Company has notified the Trustee that the net sales for Abraxane in the year ended December 31, 2022, did not meet the threshold required for a Net Sales Payment under the CVR Agreement. This notification is significant as it confirms no immediate payout is due to CVR holders based on 2022 performance. The CVRs were tied to specific pipeline products of Celgene, including Abraxane, acquired as part of the broader Celgene integration. While this filing addresses the 2022 performance, BMY retains the right to disclose future Net Sales Payments if subsequent performance metrics are met and disclosed on their investor website.

Bristol Myers Squibb (BMY) reported its 2022 financial results, highlighting significant progress in its product portfolio and strategic initiatives. The company's performance was driven by key therapeutic areas, with a focus on innovation and expanding market access for its treatments. Investors should note the company's ongoing commitment to research and development, which remains a cornerstone of its long-term growth strategy, as well as its disciplined approach to capital allocation, including strategic acquisitions and share repurchases. The company navigated a complex operating environment, underscored by factors such as global economic conditions, regulatory landscapes, and competitive pressures within the pharmaceutical industry. BMY's management discussed its financial condition and results of operations, emphasizing revenue streams, cost management, and cash flow generation. The filing also detailed risk factors that could impact future performance, providing transparency for investors assessing potential challenges and opportunities.

Bristol Myers Squibb (BMY) has filed an 8-K report on February 2, 2023, to announce its financial results for the fourth quarter and full year of 2022. The report primarily directs investors to accompanying press releases, supplemental information, and presentations available on the company's website for detailed financial and operational insights. This filing serves as a formal notification of the release of these results, allowing investors to access comprehensive data regarding the company's performance. Investors are encouraged to review the furnished exhibits, including the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2), which contain the core financial figures and reconciliations for non-GAAP measures. Additionally, the Bristol Myers Presentation (Exhibit 99.3) offers further context on financial and operating initiatives. It's important to note that the information furnished under Regulation FD is not considered 'filed' for legal liability purposes under Section 18 of the Exchange Act, but it provides crucial data for investment decision-making.

Bristol Myers Squibb Company (BMY) has filed an 8-K report on January 30, 2023, announcing the departure of Dr. Rupert Vessey, Executive Vice President of Research and Early Development, effective July 3, 2023. This executive transition marks a notable change in the company's research leadership. While Dr. Vessey's departure is confirmed, the company has outlined the financial and equity arrangements associated with his exit. Investors should note the specific details regarding Dr. Vessey's severance benefits, which will be in line with the company's Senior Executive Severance Plan. Additionally, his equity awards, including Market Share Units (MSUs) and Performance Share Units (PSUs), will vest on a pro-rated basis. Notably, his 2019 Restricted Stock Units Inducement Award will vest in full. He will also receive a pro-rated annual incentive payout for 2023. These details provide transparency on the financial implications of this executive departure.